The development of targeted medicine has greatly expanded treatment options and spurred
new research avenues in cancer therapeutics, with monoclonal antibodies (mAbs) emerging …

Human serum albumin (HSA)-based therapeutics have attracted tremendous attention in the
development of anticancer agents. The versatile properties of HSA make HSA-based …

Abstract The coronavirus disease 2019 (COVID‐19) pandemic has become a serious
burden on global public health. Although therapeutic drugs against COVID‐19 have been …

Apolipoprotein A1 (Apo-A1) is a well-recognized biomarker in tissues, closely associated
with cardiovascular diseases such as atherosclerosis, coronary artery disease, and heart …

Background: Antibodies and derivative drugs targeting immune checkpoints have been
approved for the treatment of several malignancies, but there are fewer responses in …

The new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes the
coronavirus disease 2019 (COVID-19) has significantly altered people's way of life. Despite …

Pichia pastoris is the most widely used microorganism for the production of secreted
industrial proteins and therapeutic proteins. Recently, this yeast has been repurposed as a …

Cancer is a complicated, adaptable, and heterogeneous disease caused by a wide variety
of genetic changes that might impair ability of cells to function normally. The majority of the …

Abstract PD-L1/PD-1 signaling pathway is unarguably the hottest target for developing
therapeutics against various types of cancers. With elucidation of crystal structure of PD …

Cancer is a heterogeneous disease, requiring treatment tailored to the unique phenotype of
the patient's tumor. Monoclonal antibodies (mAbs) and variants thereof have enabled …